US Earnings Financial Results SEC Filings — May 13, 2026

13-05-2026

Semnur Pharmaceuticals reported a sharply widened net loss of $4,576 thousand for Q1 2026 compared to $665 thousand in Q1 2025, driven by R&D expenses surging to $1,266 thousand (up 577% YoY) and G&A expenses to $3,310 thousand (up 592% YoY), resulting in total operating expenses of $4,576 thousand (up 588% YoY). Total assets increased to $1,969 thousand from $1,346 thousand at December 31, 2025, with cash rising to $103 thousand from $20 thousand, but liabilities grew to $27,295 thousand from $22,096 thousand, largely due to a related party loan increase to $16,915 thousand, deepening stockholders' deficit to $25,326 thousand. While financing activities provided $2,753 thousand net cash (up from $394 thousand), operating cash use intensified to $2,670 thousand from $399 thousand.

• · Net cash used in operating activities: $2,670 thousand in Q1 2026 vs $399 thousand in Q1 2025.
• · Net cash provided by financing activities: $2,753 thousand in Q1 2026 (primarily $3,503 thousand from related party loans, offset by $750 thousand promissory note repayment).
• · Stock-based compensation: $1,484 thousand in Q1 2026 vs $92 thousand in Q1 2025.
• · Property and equipment, net remained flat at $750 thousand.
• · Net loss per share: $(0.02) basic and diluted in Q1 2026 vs $(0.01) in Q1 2025.

13-05-2026

Bogota Financial Corp. reported net income of $705,946 for Q1 2026, down 3.4% YoY from $730,947, despite net interest income rising 23.2% YoY to $4,426,491 driven by lower interest expense. Total assets declined 3.0% QoQ to $877.2M, with deposits dropping 7.9% QoQ to $600.9M and loans net decreasing 1.4% QoQ to $639.4M, while stockholders' equity increased 0.8% QoQ to $142.1M. Non-interest income fell sharply 63.9% YoY to $321K, primarily due to lower bank-owned life insurance gains.

• · Provision for credit losses of $50,000 in Q1 2026 vs recovery of $80,000 in Q1 2025.
• · EPS basic and diluted remained flat at $0.06 YoY.
• · Short-term FHLB advances increased to $58.5M from $20M QoQ.

13-05-2026

BRILLIANT N.E.V. CORP. reported no revenues for the three months ended October 31, 2025, with a net loss of $498, a slight 0.4% improvement from $500 in the year-ago period due to marginally lower general and administrative expenses ($498 vs $500). Cash used in operating activities decreased significantly to $201 from $599 YoY, but the cash balance declined quarter-over-quarter to $5,547 from $5,748 amid ongoing operational cash burn. Stockholders' deficit worsened slightly to $(43,796) from $(43,298) QoQ.

• · Total current assets declined to $5,547 from $5,847 QoQ.
• · Prepaid expenses decreased to $0 from $99 QoQ.
• · Loans from related party remained flat at $49,145.
• · Common stock par value $0.001, authorized 345,000,000 shares.

13-05-2026

Principal Credit Real Estate Income Trust reported net income of $1,889 thousand for Q1 2026, a turnaround from a $971 thousand net loss in Q1 2025, driven by total revenue growth of 59% YoY to $6,734 thousand and lower expenses. However, investments in loans receivable declined 6% QoQ to $353,158 thousand from $377,308 thousand, leading to total assets decreasing 4% QoQ to $383,964 thousand. Shareholders' equity improved significantly, rising 120% QoQ to $6,682 thousand, while loans payable fell 7% QoQ to $258,646 thousand.

• · Operating cash flow improved to $2,676 thousand in Q1 2026 from $(305) thousand used in Q1 2025.
• · Net cash from investing activities $23,759 thousand in Q1 2026 (driven by $25,000 thousand loan repayments) vs $(75,512) thousand used in Q1 2025.
• · Goldman Repurchase Agreement: $142,927 thousand outstanding, fair value $142,979 thousand, available capacity $107,073 thousand.
• · Citi Repurchase Agreement: $115,575 thousand outstanding, fair value $115,667 thousand, available capacity $134,425 thousand.
• · Cash and cash equivalents increased to $20,700 thousand as of Mar 31, 2026 from $10,547 thousand as of Dec 31, 2025.

13-05-2026

NMF SLF I, Inc. reported a net increase in net assets from operations of $1,648 for Q1 2026, down sharply 92% YoY from $21,842, driven by total investment income declining 8% YoY to $34,505 amid lower interest income, partially offset by reduced expenses, though marred by $21,297 unrealized depreciation versus only $383 prior year. Net assets fell 2% QoQ to $957,927 with NAV per share dropping to $10.01 from $10.23, while net borrowings improved to $500,650 from $567,179. Distributions of $23,552 were declared, contributing to a net decrease in net assets of $21,904 for the quarter.

• · Net borrowings decreased 12% QoQ to $500,650 from $567,179.
• · Cash and cash equivalents declined to $21,645 from $25,285 QoQ.
• · Proceeds from sales and paydowns of investments: $60,932 in Q1 2026 vs $54,808 YoY.
• · Purchases of investments: $24,845 in Q1 2026 vs $27,718 YoY.

13-05-2026

For the three months ended March 31, 2026, Lincoln National Life Insurance Co reported total revenues of $4,641, up 17.9% YoY from $3,937, driven by higher net investment income (+9.4%) and realized gains of $366 versus a $248 loss. However, expenses rose to $4,786 (up 5.7% YoY), resulting in a net loss of $93 (improved from $439 loss YoY) and comprehensive income of $63; total assets declined 2.4% QoQ to $422,397 while stockholder's equity fell 1.7% QoQ to $11,784.

• · Insurance premiums declined 1.5% YoY to $1,602 from $1,627.
• · Realized gain of $366 in Q1 2026 vs loss of $248 in Q1 2025.
• · Market risk benefit loss increased to $711 from $618 YoY.
• · Net cash provided by operating activities $307 vs used $257 YoY.
• · Cash and invested cash decreased $2,241 QoQ to $5,705.

13-05-2026

Momentus Inc. reported service revenue of $3,215 thousand for Q1 2026, a 899% YoY increase from $322 thousand, driving gross profit to $1,817 thousand. However, operating expenses rose 62% to $10,509 thousand, resulting in an operating loss of $8,692 thousand and net loss of $9,480 thousand, wider than the prior year's net loss of $6,172 thousand. Share-based compensation remained elevated at $322 thousand, matching total stock compensation expense.

• · Options outstanding stable at 2,424 as of March 31, 2026, with weighted-average exercise price $632.86.
• · RSUs outstanding increased to 126,643 from 42,604 as of December 31, 2025.
• · Total dilutive securities rose to 2,359,385 in Q1 2026 from 289,409 in Q1 2025.
• · Cash paid for interest $65 thousand; operating lease payments $419 thousand in Q1 2026.

13-05-2026

Astronics Corp (ATROB) reported robust Q1 2026 financial results with sales increasing 12.0% YoY to $230,619 thousand, gross profit rising 23.5% to $75,133 thousand, operating income more than doubling by 107.3% to $27,230 thousand, and net income surging 168.0% to $25,540 thousand. However, net cash provided by operating activities declined 48.6% YoY to $10,606 thousand due to working capital outflows including higher accounts receivable and inventories, leading to a $6,313 thousand decrease in cash and equivalents to $11,867 thousand, exacerbated by elevated capital expenditures of $11,160 thousand. Total assets grew 5.7% to $747,143 thousand from year-end 2025, supported by equity expansion to $161,702 thousand.

• · Accounts Receivable increased $12,352 thousand from December 31, 2025 to April 4, 2026, using $13,420 thousand in operating cash flow YoY.
• · Inventories rose $15,085 thousand quarter-over-quarter, contributing to $16,404 thousand YoY cash outflow.
• · Long-term Debt stable at approximately $334,885 thousand as of April 4, 2026.
• · Basic EPS $0.71 vs $0.27 YoY; Diluted EPS $0.67 vs $0.26 YoY.
• · Interest Paid $2,668 thousand in Q1 2026.

13-05-2026

For the three months ended March 31, 2026, New Mountain Guardian IV Income Fund reported total investment income of $11,427 thousand, up 14% YoY from $10,032 thousand, driven by higher interest income, with net investment income increasing 23% YoY to $8,925 thousand. However, net unrealized depreciation of $7,363 thousand (vs $843 thousand YoY) and realized losses of $264 thousand resulted in a net operations increase of only $1,298 thousand, down 80% YoY from $6,389 thousand, leading to members' capital declining to $501,846 thousand (down 1.5% QoQ) and NAV per unit falling to $9.79 from $9.94 QoQ. Distributions declared totaled $8,865 thousand, up from $7,394 thousand YoY.

• · Cash and cash equivalents declined to $24,395 thousand from $35,000 thousand QoQ.
• · Total liabilities increased to $14,080 thousand from $11,287 thousand QoQ.
• · Net cash used in operating activities improved to $1,210 thousand used from $9,765 thousand used YoY.
• · First Lien investments showed net unrealized depreciation of $4,041 thousand in Q1 2026.
• · Investment purchases totaled $25,682 thousand in Q1 2026, with proceeds from sales/paydowns at $16,452 thousand.

13-05-2026

Revenues were nearly flat, up 0.2% YoY to $435,775 for the three months ended April 4, 2026, while the net loss widened significantly to $10,685 from $3,258 in the prior year period due to higher general and administrative expenses ($49,199 vs. $40,600) and depreciation ($21,256 vs. $18,568). Total assets grew 7.6% QoQ to $1,612,555 driven by acquisitions and higher cash ($28,212 vs. $12,397), but long-term debt increased to $459,997 from $317,279 and common shareholders' equity declined to $122,876 from $143,052. Operating cash flow deteriorated to $(17,978) used from $(4,391) used YoY amid higher capex and business purchases.

• · Accounts receivable, net increased to $393,085 from $385,470 QoQ.
• · Goodwill rose to $125,785 from $98,723 QoQ due to business combinations.
• · Capital expenditures on equipment $25,090 and land/buildings $12,162.
• · Shares repurchased for treasury $13,305.
• · Dividend $0.030 per share, total $1,212.

13-05-2026

Kennedy Lewis Capital Co's Q1 2026 10-Q shows total investment income of $30,682,777, up 33% YoY from $23,097,252, with net investment income rising 39% YoY to $17,080,995, contributing to a net increase in net assets from operations of $16,871,658, up 84% YoY. However, total investments at fair value declined 1.2% QoQ to $1,096,362,224 from $1,109,977,047 amid net unrealized depreciation of $457,982, and NAV per Class I share edged down to $20.00 from $20.04 QoQ. Total net assets grew 5.4% QoQ to $744,822,375, supported by share issuances and reinvestments.

• · Secured Credit Facility remained flat at $412,500,000 QoQ.
• · Cash and cash equivalents decreased to $5,496,329 from $60,216,576 QoQ; restricted cash increased to $44,269,851 from $32,440,987.
• · Net cash used in operating activities was $40,902,980 for Q1 2026.
• · Common shares outstanding increased to 37,246,308 from 35,262,120 QoQ.

13-05-2026

For the three months ended March 31, 2026, Strategic Student & Senior Housing Trust, Inc. reported leasing and related revenues of $10,223,590, up 13.1% YoY from $9,040,180, leading to income from operations of $949,286, a 203.7% increase from $312,614. However, the company recorded a net loss of $302,308, an improvement from $1,042,092 YoY but still negative, with property operating expenses rising 8.8% to $6,887,268 and total equity declining to $7,004,057 from $7,687,989 at December 31, 2025. Cash from operations strengthened to $1,489,242, up 68.2% YoY.

• · Net cash provided by operating activities increased to $1,489,242 in Q1 2026 from $885,605 in Q1 2025.
• · Debt, net decreased to $101,947,470 as of March 31, 2026 from $102,406,080 at December 31, 2025.
• · Accumulated depreciation increased to $41,728,809 from $40,271,844 QoQ.
• · Cash and cash equivalents rose to $4,440,994 from $3,010,009 QoQ.

13-05-2026

CareView Communications Inc reported Q1 2026 total revenues of $2,191,342, down 2% YoY from $2,239,347, driven by a 17% decline in sales-based software bundle revenue to $935,654 despite growth in subscription-based revenue (+3% to $1,017,483) and equipment packages (+97% to $238,205). Operating income improved to $30,843 from a $134,710 loss YoY due to 9% lower operating expenses, resulting in a smaller net loss of $756,200; however, cash flows from operations turned negative at $126,166 from $267,881 YoY, reducing cash to $1,411,435.

• · Accrued interest payable increased to $23,698,264 as of Mar 31, 2026 from $22,896,139 at Dec 31, 2025.
• · Stock-based compensation expense of $150,302 in Q1 2026.
• · Contract liabilities balance decreased to $2,618,960 end Q1 2026 from $3,158,474 end Q1 2025.

13-05-2026

Kadant Inc reported revenue of $281,505 thousand for the three months ended April 4, 2026, up 17.7% YoY from $239,210 thousand, driven by higher sales, while operating income rose 12.7% to $40,109 thousand. However, net cash provided by operating activities declined 4.0% to $21,916 thousand, comprehensive income attributable to Kadant fell to $22,053 thousand from $34,007 thousand due to a $3,486 thousand foreign currency translation loss, and diluted EPS growth slowed to 5.9% at $2.16. Total assets remained stable at $1,714,652 thousand.

• · Interest expense increased to $4,484 thousand from $3,822 thousand YoY.
• · Cost of revenue rose 20.1% YoY to $154,802 thousand.
• · Cash and cash equivalents decreased to $117,025 thousand from $119,551 thousand at January 3, 2026.

13-05-2026

Rare Element Resources Ltd reported a narrowed net loss of $2,133 for Q1 2026 compared to $2,395 in Q1 2025, driven by lower operating expenses of $2,340 versus $2,672 YoY, while cash and total assets surged to $47,141 and $52,627 respectively from $19,315 and $24,120 at year-end 2025 due to a $30,478 rights offering. However, net cash used in operating activities increased to $2,725 from $2,269 YoY, and the accumulated deficit grew to $183,123 from $180,990. Shares outstanding rose to 645,368,390 from 516,134,712 QoQ amid the financing.

• · Exploration and evaluation expenses: $1,719 in Q1 2026 vs $1,877 in Q1 2025
• · Corporate administration expenses: $580 in Q1 2026 vs $750 in Q1 2025
• · Non-operating income: $207 in Q1 2026 vs $277 in Q1 2025
• · Accumulated deficit: $183,123 as of March 31, 2026

13-05-2026

For Q1 2026, Sensus Healthcare reported revenues of $3.4M, down 59% YoY from $8.3M, primarily due to a 75% drop in point-in-time product revenue to $1.7M, resulting in gross profit falling 77% to $1.0M and operating loss widening to $4.4M from $2.6M. Operating expenses decreased 24% YoY to $5.3M, driven by cuts in selling/marketing (-21%) and R&D (-39%), leading to a net loss of $2.6M similar to prior year aided by a $1.6M tax benefit. Cash and equivalents declined 17% QoQ to $18.3M amid $3.8M used in operations.

• · Remaining deferred revenue as of Mar 31 2026: $0.6M total ($0.1M product, $0.6M service).
• · Inventories increased to $16.5M from $14.6M QoQ.
• · Net cash used in operating activities: $3.8M in Q1 2026 vs $2.7M in Q1 2025.
• · Tax benefit of $1.6M in Q1 2026 vs provision of $0.1M in Q1 2025.

13-05-2026

UTG Inc's Q1 2026 net income attributable to common shareholders surged 81% YoY to $23,436,868 from $12,952,643, propelled by total net investment gains of $31,762,259 versus $17,266,251 prior year, leading to total revenue of $36,493,614, up 67% YoY. Total assets expanded 6% QoQ to $521,392,599 from $491,368,581, with cash and equivalents rising 53% to $46,771,832. However, premiums and policy fees fell 6% YoY to $1,796,689, fixed maturities declined 1% QoQ to $72,174,265, and net cash from operations remained negative at $(2,598,871).

• · Gross unrealized losses on fixed maturities increased to $2,270,006 as of March 31, 2026 from $1,949,786 at December 31, 2025.
• · Net cash used in operating activities improved to $(2,598,871) from $(3,255,211) YoY.
• · Basic EPS increased to $7.46 from $4.10 YoY.
• · Share repurchases: Treasury shares acquired and retired for $195,773.

13-05-2026

The Canary Litecoin ETF reported a QoQ decline in net assets to $6,216,656 as of March 31, 2026, from $6,960,107 at December 31, 2025, driven by a net decrease from operations of $(2,666,242) due to unrealized depreciation of $(2,118,115) and realized losses of $(531,647) on Litecoin investments. While shares outstanding increased 27% to 470,000 amid $2,646,019 in shares sold, NAV per share fell sharply 30% to $13.23. Litecoin holdings grew in quantity to 115,005 from 90,747, but fair value dropped 11% to $6,221,839 reflecting cryptocurrency price depreciation.

• · Paid-in capital increased to $10,738,775 from $8,815,984, while accumulated deficit deepened to $(4,522,119) from $(1,855,877).
• · 40,000 shares redeemed across Q1 2026 at average prices declining from $16.54 in January to $13.28 in March.
• · Investments in Litecoin at cost: $10,182,602 as of March 31, 2026.

13-05-2026

Stereotaxis, Inc. reported Q1 2026 total revenue of $6,291 thousand, down 15.8% YoY from $7,472 thousand, with systems revenue declining 32.8% to $1,319 thousand and disposables, service, and accessories down 9.7% to $4,972 thousand. Operating loss widened slightly to $5,981 thousand from $5,929 thousand, despite a 2.2% reduction in operating expenses to $9,775 thousand. However, cash and equivalents increased 8.9% QoQ to $14,616 thousand, bolstered by $4,716 thousand in net financing proceeds from stock issuance.

• · Current deferred revenue increased to $6,541 thousand from $5,675 thousand QoQ.
• · Contingent consideration increased to $10,374 thousand total ($5,266 current + $5,108 long-term) from $9,618 thousand.
• · Stock-based compensation expense was $2,110 thousand in Q1 2026, down from $2,535 thousand in Q1 2025.
• · Net cash used in operating activities increased to $3,442 thousand from $1,779 thousand YoY.

13-05-2026

Pismo Coast Village Inc reported results for the three and six months ended March 31, 2026, with quarterly revenue increasing 13% YoY to $2,223,000 from $1,966,000, driven by 15% growth in resort operations to $2,031,000, while achieving operating income of $64,000 versus a $187,000 loss prior year. For the six months, revenue rose 13% to $4,536,000, with net income of $111,000 versus a $160,000 loss, but retail operations declined 4% to $279,000 and property lease income fell 11% to $101,000, resulting in a modest six-month operating loss of $14,000. Total assets grew to $31,649,000 from $30,529,000 at September 30, 2025.

• · Net cash provided by operating activities was $1,543,000 for six months ended March 31, 2026, slightly down from $1,545,000 prior year.
• · Capital expenditures of $213,000 in six months ended March 31, 2026, up from $113,000.
• · Property and equipment, net decreased slightly to $16,573,000 from $16,588,000.
• · Customer deposits increased to $3,977,000 from $2,596,000.

13-05-2026

OMEROS CORP reported net income of $56.1M for Q1 2026, a significant turnaround from a $33.5M net loss in Q1 2025, driven primarily by a $73.1M non-cash gain on financial instruments and $9.9M in product sales versus none prior year; R&D expenses declined 44% YoY to $13.4M while SG&A rose 20% to $13.4M. However, the company posted an operating loss of $17.4M (improved from $35.0M YoY), cash and equivalents dropped sharply to $1.9M from $9.7M QoQ amid $15.0M net cash used in operations, and total assets fell 12% QoQ to $286.2M.

• · 2026 Notes fully repaid at maturity on February 15, 2026.
• · OMIDRIA royalty obligation principal payments of $4.7M in Q1 2026.
• · Weighted-average diluted shares: 90,116,352 in Q1 2026 vs 58,056,357 in Q1 2025.
• · Cash paid for interest: $5.6M in Q1 2026.

13-05-2026

Embassy Bancorp, Inc. reported Q1 2026 net income of $3,739 thousand (up 29.5% YoY from $2,887 thousand) and basic/diluted EPS of $0.50 (up from $0.38), driven by net interest income growth of 16.4% YoY to $11,441 thousand. Total assets increased 2.3% QoQ to $1,841,972 thousand, with deposits up 2.5% to $1,681,828 thousand and loans up 0.4% to $1,283,791 thousand. However, comprehensive loss was $168 thousand (vs. $5,642 thousand income YoY) due to $3,907 thousand net unrealized loss on securities, resulting in stockholders' equity declining 2.2% QoQ to $124,807 thousand; non-interest expenses also rose 9.5% YoY to $7,559 thousand.

• · Provision for credit losses: $20 thousand in Q1 2026 (down from $47 thousand YoY)
• · Net cash provided by operating activities: $4,831 thousand in Q1 2026 (up from $2,684 thousand YoY)
• · Treasury stock purchases: 150,000 shares for $2,959 thousand in Q1 2026
• · Cash and cash equivalents: $141,833 thousand as of March 31, 2026 (up $28,974 thousand QoQ)

13-05-2026

Linkhome Holdings Inc. reported Q1 2026 net revenues of $4,907,470, down 14.0% YoY from $5,709,426, driven by sharp declines in real estate service revenue (to $74,470 from $229,536) and Cash Offer revenue (to $4,833,000 from $5,479,890). Gross profit decreased 29.0% to $186,028 amid higher cost of revenues, while operating expenses surged to $400,328 from $138,095, leading to an operating loss of $214,300 versus a $123,822 profit in Q1 2025. The company recorded a net loss of $134,670 ($0.01 per share) compared to net income of $80,629 last year, with cash and equivalents dropping to $3,471,824 from $7,018,931 at December 31, 2025.

• · Net cash used in operating activities increased to $3,292,646 in Q1 2026 from $844,832 in Q1 2025.
• · Total current liabilities decreased to $457,021 as of March 31, 2026 from $2,082,601 at December 31, 2025.
• · General and administrative expenses rose to $393,358 in Q1 2026 from $120,754 in Q1 2025.

13-05-2026

For Q1 2026, ECA Marcellus Trust I reported royalty income of $1,792,578, up 40% YoY from $1,278,647, leading to distributable income of $1,583,025 (up 74% YoY) or $0.090 per unit (vs. $0.052). However, the Trust Corpus declined to $12,527,658 from $13,192,593 YoY due to amortization of $275,056 and distributions, while net royalty interest in gas properties fell 3% QoQ to $8,867,070. Total assets grew to $14,110,683 from $13,321,836 QoQ, supported by higher cash and receivables.

• · Cash reserves withheld by Trustee: $90,000 (flat YoY)
• · Interest withheld on cash reserves Q1 2026: $24,658 (down from $26,420 YoY)
• · 17,605,000 common units authorized, issued and outstanding

13-05-2026

The Canary Staked SUI ETF (SUIS) launched on February 17, 2026, reported net assets of $24,184,075 as of March 31, 2026, with 1,060,000 shares outstanding at a NAV of $22.82 per share, driven by $26,459,775 in capital inflows from shares sold. The fund generated $43,073 in staking income, resulting in net investment income of $21,339 after $21,734 sponsor fees; however, it recorded a net operational loss of $2,275,700 due to $2,295,737 unrealized depreciation and a $1,302 realized loss on SUI investments. Investments in SUI totaled $24,200,340 at fair value (27,492,860 SUI tokens), compared to a cost basis of $26,496,077.

• · Payable to Sponsor: $16,265
• · Fund inception date: February 17, 2026 (beginning net assets: $0)

13-05-2026

Auburn National Bancorporation reported Q1 2026 net earnings of $2,198 thousand, up 43.7% YoY from $1,530 thousand, supported by 9.7% YoY growth in net interest income to $7,733 thousand and 19.5% increase in noninterest income, while noninterest expense remained flat at $5,901 thousand. Loans grew 3.0% QoQ to $582,040 thousand and deposits rose 0.9% to $931,109 thousand, but securities available-for-sale declined 2.8% QoQ to $226,785 thousand. Comprehensive income fell to $1,949 thousand from $5,766 thousand YoY due to a $249 thousand unrealized loss on securities.

• · Provision for credit losses released $76 thousand in Q1 2026 vs $10 thousand in Q1 2025.
• · EPS basic and diluted $0.63 in Q1 2026 vs $0.44 in Q1 2025.
• · Cash dividends paid $0.27 per share in both Q1 2026 and Q1 2025.
• · 3,493,256 common shares outstanding as of May 12, 2026.

13-05-2026

Unite Acquisition 2 Corp. reported a net loss of $72,013 for Q1 2026, up 17% YoY from $61,644, driven by higher general and administrative expenses of $63,876 (up 19% YoY). Cash balance declined to $417 from $886 at year-end 2025, while total liabilities rose to $525,699 (up 16% QoQ) amid increasing payables and notes; however, net cash used in operations improved slightly to $2,969 from $10,981 YoY. Stockholder's deficit widened to $525,282 from $453,269 QoQ.

• · Loss per common share: $0.014 (Q1 2026) vs. $0.012 (Q1 2025).
• · Note payable to stockholder increased to $92,500 from $90,000 QoQ.
• · Accrued interest on Lucius note: $46,923 (up from $38,786 QoQ).

13-05-2026

The Canary XRP ETF reported a significant decline in net assets to $264,767,022 as of March 31, 2026, down 18% from $322,819,725 at December 31, 2025, driven by a $94.7M unrealized depreciation in XRP holdings and a net decrease from operations of $95.3M. NAV per share fell 27% to $14.28 from $19.58, while shares outstanding increased 12% to 18,540,000 amid $38M in share sales, partially offsetting the losses with $37.3M net capital inflow. XRP investments dropped 18% in value to $264,883,295 despite a quantity increase to 197,214,584 tokens.

• · Sponsor fees for Q1 2026: $374,999.
• · 30,000 shares redeemed in January 2026 at average price of $22.87 per share.
• · Investments in securities at cost: $429,153,979 as of March 31, 2026.

13-05-2026

The Canary Marinade Solana ETF (SOLC) reported net assets of $1,145,618 as of March 31, 2026, down 40.5% from $1,926,808 at December 31, 2025, with NAV per share declining 32.0% to $16.37 from $24.09 amid significant unrealized depreciation of $539,756 on Solana holdings. While staking income provided $21,975 in net investment income, operations resulted in a net decrease of $551,958 due to realized losses of $34,177, and capital share transactions showed net outflows of $229,232 from redemptions exceeding sales. Shares outstanding fell 12.5% to 70,000 from 80,000.

• · Sponsor fees of $1,691 fully waived for the quarter ended March 31, 2026.
• · 20,000 shares redeemed in January 2026 at average price of $25.49 per share; no redemptions in February or March 2026.
• · Investments in Solana at cost: $1,854,598 at March 31, 2026 (vs. fair value $1,145,618); $2,096,032 at December 31, 2025 (vs. fair value $1,926,808).

13-05-2026

Tamboran Resources reported no revenue for the three months ended March 31, 2026, with net loss attributable to stockholders increasing 41% YoY to $9.4M from $6.7M, though the nine-month loss improved 9% to $24.2M from $26.7M. Total assets expanded 51% to $672M from $446M at June 30, 2025, supported by $110M in common stock proceeds and $55M NCI contributions, boosting cash and equivalents to $102M. However, operating cash use rose 17% to $27M over nine months, driven by $80M exploration payments and $112M total investing outflows.

• · Unproved properties increased to $465M from $342M.
• · Payments for exploration and evaluation: $79,739 thsd in 9 months 2026 vs $74,078 thsd 2025.
• · Net cash from financing activities: $194M in 9 months 2026 vs $48M 2025.
• · Foreign currency translation gain contributed to comprehensive income of $3.9M attrib to stockholders in Q3.

13-05-2026

For Q1 2026, Aquestive Therapeutics reported revenues of $14,446, up 66% YoY from $8,720, with significant improvements in selling, general, and administrative expenses which fell 42% to $10,977. Net loss narrowed to $8,057 from $22,930 YoY, and loss per share improved to $(0.07) from $(0.24). However, the company continues to report operating losses of $4,204, cash used in operations increased usage to $14,806 from $23,400 but cash position declined to $110,734 from $121,169 at year-end amid ongoing burn.

• · Research and development expenses decreased 22% YoY to $4,204 from $5,361.
• · Net cash used for operating activities was $14,806 in Q1 2026 vs $23,400 in Q1 2025.
• · Stockholders’ deficit increased slightly to $(34,054) from $(33,662) at Dec 31, 2025.

13-05-2026

AYTU BioPharma's Q3 FY2026 net revenue declined 33% YoY to $12,411 thousand from $18,452 thousand, with ADHD Portfolio down 41% to $9,093 thousand, Pediatric Portfolio down 70% to $921 thousand, offset partially by new EXXUA revenue of $2,397 thousand; for the nine months, revenue fell 19% to $41,464 thousand. The company reported a Q3 net loss of $5,618 thousand versus prior year profit of $3,994 thousand, and nine-month net loss of $14,237 thousand versus $6,256 thousand profit, with operating cash use improving to $1,125 thousand from $4,740 thousand. Stockholders' equity rose to $35,143 thousand from $18,966 thousand at June 30, 2025, boosted by warrant exercises and derivative reclassification.

• · Total current liabilities decreased to $59,972 thousand from $63,064 thousand at June 30, 2025.
• · Derivative warrant liabilities fell sharply to $2,182 thousand from $26,334 thousand.
• · Inventories declined to $7,460 thousand from $11,434 thousand, with finished goods down significantly.
• · Net cash used in operating activities for nine months improved to $1,125 thousand from $4,740 thousand.

13-05-2026

Dermata Therapeutics reported a narrowed net loss of $1,847,706 for Q1 2026, improving 19.8% YoY from $2,303,587 in Q1 2025, primarily due to a 70.1% reduction in R&D expenses to $383,724, though SG&A expenses rose 45.7% to $1,542,658. Cash and equivalents decreased $576,696 QoQ to $6,945,282 as of March 31, 2026 from $7,521,978 at December 31, 2025, amid higher net cash used in operations of $2,479,718 versus $1,934,066 YoY. Stockholders' equity increased to $6,413,003, supported by $1,994,051 net proceeds from ATM common stock sales.

• · Weighted-average shares outstanding increased to 3,858,921 in Q1 2026 from 515,465 in Q1 2025, improving EPS to $(0.48) from $(4.47).
• · New inventory of $93,091 (raw materials) as of March 31, 2026.
• · 5,424,598 warrants outstanding as of March 31, 2026.
• · Net cash provided by financing activities $1,903,022 in Q1 2026, down significantly from $8,491,764 in Q1 2025.

13-05-2026

Grocery Outlet Holding Corp. reported net sales of $1,166,352 thousand for the 13 weeks ended April 4, 2026, up 3.6% YoY from $1,125,567 thousand, with perishable sales increasing 2.4% to $440,987 thousand and non-perishable up 4.4% to $725,365 thousand. However, a $158,000 thousand goodwill impairment, alongside higher SG&A expenses of $347,022 thousand (up 4.8% YoY), resulted in an operating loss of $178,014 thousand and net loss of $180,322 thousand, significantly worse than the prior year's $22,508 thousand and $23,317 thousand losses. Operating cash flow was $52,558 thousand, down 10.8% from $58,938 thousand YoY.

• · Goodwill decreased to $475,835 thousand from $633,835 thousand QoQ due to $158,000 thousand impairment.
• · Total stockholders' equity declined to $807,096 thousand from $983,663 thousand at January 3, 2026.
• · Property and equipment, net increased to $755,562 thousand from $742,961 thousand QoQ.
• · Restructuring charges decreased to $18,191 thousand from $33,875 thousand YoY.

13-05-2026

Snail, Inc. reported Q1 2026 revenues of $27,294,654, up 35.8% YoY from $20,110,872, with gross profit more than doubling to $11,656,441 from $5,847,527 and swinging to operating income of $2,040,343 from a $4,100,838 loss, resulting in net income of $2,134,556 versus a prior-year loss. Operating cash flow strengthened significantly to $10,207,831 from $764,549, boosting cash to $14,259,168. However, total assets declined 4.2% QoQ to $56,841,764 from $59,307,138, accounts receivable fell 26.5% QoQ to $9,206,357, and related party accounts payable rose to $21,648,949 from $20,067,013.

• · Accounts payable – related parties increased to $21,648,949 as of March 31, 2026 from $20,067,013 as of Dec 31, 2025.
• · Revolving loan reduced to $2,500,000 from $5,000,000 QoQ.
• · Weighted-average Class A shares basic: 9,036,135 (Q1 2026) vs 8,442,025 (Q1 2025).
• · Software license royalties – related parties: $6,333,981 (Q1 2026) vs $5,273,727 (Q1 2025).

13-05-2026

Skinvisible, Inc. reported flat revenues of $5,000 for Q1 2026 versus Q1 2025, with operating expenses declining 9.6% to $130,938, leading to a reduced net loss of $267,184 from $281,005 YoY. However, cash balances fell to $1,798 from $2,620 at December 31, 2025 (down 31.4% QoQ), total liabilities increased to $10,649,384 from $10,390,348 QoQ, and stockholders' deficit worsened to $10,529,965.

• · No cost of revenues or investing cash flows in Q1 2026.
• · No cash paid for interest or taxes in Q1 2026.
• · Patents and trademarks, net: $95,029 at March 31, 2026 (down from $100,036 at Dec 31, 2025).

13-05-2026

TELA Bio reported Q1 2026 revenue of $19,059, up 3% YoY from $18,520, with gross profit remaining nearly flat at $12,520. However, net loss widened to $12,273 from $11,264 YoY due to higher operating expenses ($23,046 vs $22,984) and interest expense, while cash and equivalents fell to $39,541 from $50,845 QoQ and stockholders' equity shifted to a $5,201 deficit from $6,313.

• · Inventory excess and obsolescence charge increased to $935 in Q1 2026 from $630 in Q1 2025.
• · Proceeds from the sale of product line were $309 in Q1 2026 vs $170 in Q1 2025.
• · Accounts receivable, net decreased to $9,715 as of March 31, 2026 from $10,347 as of December 31, 2025.

13-05-2026

Spruce Biosciences reported a narrowed net loss of $12,266 for Q1 2026 versus $14,041 in Q1 2025, driven by a 17% reduction in total operating expenses to $11,987, primarily from a 30% cut in R&D expenses to $7,575, though G&A expenses rose 21% to $4,412. Cash and cash equivalents increased to $54,080 from $48,906 QoQ, supported by $14,146 in debt proceeds, but stockholders' equity declined to $34,648 from $42,516 amid higher liabilities including $6,464 in debt and $3,938 warrant liability. Cash burn from operations improved to $8,732 used from $12,727 YoY.

• · Weighted-average shares outstanding: 1,372,084 in Q1 2026 vs 586,142 in Q1 2025.
• · Debt, total: $6,464 as of March 31, 2026 (none as of Dec 31, 2025).
• · Net cash provided by financing activities: $13,916 in Q1 2026.

13-05-2026

Dynamix Corp III reported net income of $1,204,590 for the three months ended March 31, 2026, driven by $1,790,049 in other income primarily from dividends on the Trust Account, which grew to $204,072,640 (up 0.8% QoQ). However, the company incurred an operating loss of $585,459, cash and cash equivalents declined 24.1% QoQ to $1,011,147, and shareholders' deficit worsened to $(7,223,688) from $(6,828,833). Total assets increased slightly to $205,251,701, supported by Trust Account growth, while current liabilities rose to $352,749.

• · Net cash used in operating activities: $(501,461)
• · Cash withdrawn from Trust Account for working capital: $179,981
• · Basic and diluted net income per redeemable Class A ordinary share: $0.04
• · Accretion of Class A ordinary shares to redemption amount: $(1,599,445)
• · Class A ordinary shares subject to possible redemption: 20,125,000 shares at $10.14 per share as of March 31, 2026

13-05-2026

For the three months ended March 31, 2026, WisdomTree Bitcoin Fund reported a net decrease in net assets from operations of $33.9M, an improvement from $40.3M in the prior year period due to smaller unrealized depreciation losses ($33.9M vs $91.0M) and lower sponsor fees ($87K vs $204K), though with no investment income. Net assets grew 5.4% QoQ to $147.3M from $139.7M, driven by $41.5M in share creations, but NAV per share declined 22.1% QoQ to $72.02 amid bitcoin price depreciation. YoY, ending net assets dipped 3.4% to $147.3M from $152.6M, reflecting no share redemptions this period versus significant outflows last year.

• · Bitcoin at cost: $148,025,827 (Mar 31, 2026) vs $106,564,016 (Dec 31, 2025)
• · Sponsor fee payable: $31,427 (Mar 31, 2026) vs $30,038 (Dec 31, 2025)
• · No shares redeemed in Q1 2026 vs 2,180,000 shares redeemed in Q1 2025
• · Cash at end of period: $0 (Q1 2026) vs $32,531,795 (Q1 2025)

13-05-2026

B&G Foods' 10-Q filing as of April 4, 2026 shows total assets slightly increased to $2,836.3M from $2,834.8M at January 3, 2026, driven by higher cash (+14.7% to $64.5M) and intangible assets (+6.9% to $1,274.2M), while inventories declined 15.7% to $354.5M and property, plant & equipment fell 8.3% to $232.5M. Stockholders' equity decreased 10.9% to $403.4M due to lower retained earnings (-10.9% to $389.2M), amid a 2.8% rise in long-term debt to $2,000.8M. The company noted risks from high leverage, potential debt covenant issues, pending divestiture of its Green Giant and Le Sueur business in Canada, and possible asset impairments.

• · Accumulated depreciation on PP&E: $461,778 as of April 4, 2026 (vs. $484,809 as of January 3, 2026)
• · Shares of common stock issued and outstanding: 81,167,001 as of April 4, 2026 (up from 79,977,050)
• · Forward-looking risks include compliance with debt covenants (leverage and interest coverage ratios), international trade disputes/tariffs, failure to realize synergies from acquisitions, and potential impairments of goodwill ($549.5M) and other intangibles ($1,274.2M)

13-05-2026

Avidbank Holdings, Inc. reported Q1 2026 net income of $9.0 million, up 66% YoY from $5.4 million, fueled by net interest income growth of 37% to $26.5 million on higher loan interest and lower interest expense, with basic EPS rising to $0.85 from $0.73. Total assets increased 0.4% QoQ to $2.58 billion, supported by 1.2% loan growth to $2.15 billion and 0.6% deposit growth to $2.20 billion. However, a $1.4 million provision for credit losses was recorded versus none YoY, cash equivalents fell 3.6% QoQ to $149.0 million, debt securities declined 3.4% to $210.6 million, and other comprehensive loss of $1.0 million contrasted with prior income.

• · Basic EPS $0.85 for Q1 2026 vs $0.73 YoY.
• · Diluted EPS $0.84 for Q1 2026 vs $0.71 YoY.
• · Weighted average basic shares 10,600,902 for Q1 2026 vs 7,488,051 YoY.
• · Shareholders' equity $288.4 million as of March 31, 2026, up 2.6% QoQ.
• · Non-interest bearing deposits $577.1 million, up 3.6% QoQ; interest-bearing $1,622.2 million, down 0.4% QoQ.
• · Net cash used in investing activities $20.7 million for Q1 2026.

13-05-2026

Colombier Acquisition Corp. III, a SPAC, completed its IPO in Q1 2026, raising $299,000,000 in net proceeds from 29,900,000 public units and $1,500,000 from 150,000 private placement units, resulting in $300,572,506 in the Trust Account at $10.02 per share. The company reported net income of $366,020, primarily from $1,572,506 in interest earned on Trust investments, but recorded an operating loss of $242,486 and a $964,000 compensation expense, widening shareholders' deficit to $1,424,239 from $22,937 at year-end 2025.

• · Basic and diluted net income per share of $0.01 for both Class A and Class B Ordinary Shares
• · IPO Promissory Note to related party repaid in full for $99,025
• · Net cash used in operating activities: $702,292
• · Deferred underwriting fee payable of $3,000,000
• · Accrued offering costs: $85,000 as of March 31, 2026

13-05-2026

For the quarter ended March 31, 2026, North Haven Private Income Fund's total assets increased 1.4% QoQ to $624,283, with non-controlled/non-affiliated investments rising to $596,389 from $573,558, while members' capital grew 1.9% to $306,643; however, NAV per unit declined 1.5% QoQ to $19.83. Investment income surged 72% YoY to $13,084 driven by higher interest income, leading to net investment income of $7,443 (up 53% YoY), but increased unrealized depreciation of $5,154 resulted in net operations of $2,299, down 41% YoY from $3,903. Distributions remained stable at $0.47 per unit, amid unit issuances of $22,219 offset by repurchases of $14,819.

• · Debt increased 7.6% QoQ to $295,172.
• · Cash decreased to $22,128 from $33,697 QoQ.
• · Distributions to unitholders totaled $7,365 for Q1 2026.
• · Unit repurchases amounted to $14,819 during Q1 2026.
• · Total portfolio investments at fair value $596,389 (194.49% of net assets).

13-05-2026

First National Corp (FXNC) reported Q1 2026 net income of $4,887 thousand, up 206% YoY from $1,598 thousand, fueled by net interest income growth of 7% to $18,676 thousand and noninterest expenses declining 13% to $15,982 thousand due to absence of $1,940 thousand merger costs from prior year. Total assets increased 1.9% QoQ to $2,075,823 thousand, with loans up 1.0% to $1,449,708 thousand and deposits rising 2.1% to $1,837,292 thousand. However, service charges on deposits fell 9% YoY to $924 thousand, interest on bank deposits dropped 30% to $1,170 thousand, and other comprehensive loss of $1,188 thousand contrasted with prior year's gain.

• · Provision for credit losses decreased to $450 thousand from $832 thousand YoY.
• · Earnings per share (diluted) $0.54 vs $0.18 YoY.
• · Cash and cash equivalents increased $26,899 thousand QoQ to $187,809 thousand.

13-05-2026

For the quarter ended March 31, 2026, 21Shares XRP ETF reported a significant decline in net assets to $142.1M from $247.7M at December 31, 2025, driven by a $52.3M net decrease from operations including $40.4M unrealized depreciation on XRP holdings and $72.1M in redemptions, partially offset by $18.9M in contributions. NAV per share fell 26.5% QoQ to $13.10, while shares outstanding decreased 21.9% to 10.85M. YoY, operations shifted from a modest $32K gain to a $52.3M loss, though sponsor fees dropped sharply 90.8% to $142.9K.

• · XRP cost basis: $224,608,249 at March 31, 2026 vs $289,712,269 at December 31, 2025
• · Paid-in-capital: $241,804,488 at March 31, 2026 vs $295,007,000 at December 31, 2025
• · Accumulated earnings (loss): ($99,655,857) at March 31, 2026 vs ($47,348,729) at December 31, 2025
• · Sponsor fee payable: $6,479 at March 31, 2026 vs $35,268 at December 31, 2025

13-05-2026

HUMBL reported no revenues for Q1 2026, with operating expenses rising 27% YoY to $1.75M, resulting in an operating loss of $1.75M and a net loss of $3.0M from continuing operations, though this narrowed 26% YoY from $4.0M. Total assets grew 61% QoQ to $2.2M, driven by a $695k license fee and prepaids, but cash plummeted 95% to $6.7k amid $389k operating cash burn, while liabilities increased 20% to $5.1M and stockholders' deficit widened slightly to $2.9M. Massive share dilution occurred with common shares outstanding up 10% QoQ to 59.2B.

• · Derivative liabilities increased to $1,734,193 as of March 31, 2026 from $1,400,996.
• · Convertible notes payable current portion $1,835,901 as of March 31, 2026.
• · Net cash used in operating activities $389,384 in Q1 2026.
• · Proceeds from convertible notes payable $705,000 in Q1 2026.

13-05-2026

Churchill Capital Corp XI reported net income of $3,171,373 for Q1 2026, driven by $3,545,046 in interest income from the Trust Account, which grew to $418,094,829 from $414,549,783 QoQ (+0.9%). However, the company incurred an operating loss of $373,673 from general and administrative costs, and cash balance declined sharply to $410,097 from $736,204 (-44%). Shareholders' deficit improved slightly to $(14,134,591) from $(14,211,135), with no business combination activity noted.

• · Deferred underwriting fee payable remains at $15,990,000.
• · Permitted withdrawals from Trust Account limited to $1,000,000 annually for working capital and taxes.
• · Net cash used in operating activities: $326,107 for Q1 2026.
• · Class A Ordinary Shares subject to redemption valued at approximately $10.07 per share as of March 31, 2026 (up from $10.00).

13-05-2026

STAAR Surgical reported Q1 2026 net sales of $93,522, up approximately 120% YoY from $42,589, with gross profit rising to $68,859 from $28,005 and operating income turning positive at $7,979 versus a $57,401 loss prior year, resulting in net income of $5,206 compared to a $54,211 loss. SG&A expenses declined to $60,880 from $85,406, though including $6,743 in merger costs and $2,681 in restructuring charges. However, net cash used in operating activities worsened to $21,695 from $5,734, driving cash and equivalents down to $131,864 from $153,150 quarter-over-quarter.

• · Allowance for credit losses increased to $799 from $83 QoQ.
• · Deferred income taxes decreased to $1,088 from $3,365 QoQ.
• · Total current liabilities declined to $60,994 from $68,504 QoQ.
• · Weighted average diluted shares outstanding: 50,900 in Q1 2026 vs 49,344 in Q1 2025.
• · Investments available for sale at $32,025 (April 3, 2026) vs $34,386 (Jan 2, 2026).